The iromycins reveal inhibitory activity of the mitochondrial electron transport chain at the site of complex I with only marginal cytotoxicity. Both, natural and synthetic derivatives were used for detailed SAR studies. 
Graphical Abstract The iromycins reveal inhibitory activity of the mitochondrial electron transport chain at the site of complex I with only marginal cytotoxicity. Both, natural and synthetic derivatives were used for detailed SAR studies.
Iromycins from Streptomyces sp. Total synthesis
Introduction
The respiratory chain (electron transport chain) with its particular functional complexes in the lipid bilayer membranes is one of the most important biochemical cascade reactions in the energy supply of all living organisms. 1 The enzymes, which mediate electron transfer and ATP synthesis in a sequence of oxidation-reduction reactions of the oxidative phosphorylation, are exclusively located in mitochondria or bacterial membranes, respectively. The impairment of this energy metabolism is associated with dysfunction of cells or cell death. Complex I (NADH-ubiquinone oxidoreductase) is responsible for the first step of the respiratory chain and transfers electrons from NADH to ubiquinone (coenzyme Q). This process is coupled with the transfer of two protons per electron across the membrane in complex I, which adds to the proton motive force used for ATPase synthesis, however, the precise mechanism is mainly unsolved. 2, 3, 4 Complex I is the largest and most complicated enzyme in mammals, e.g. bovine heart complex I (M = approx. 1 MDa) consists of 45 subunits, seven of them are encoded by mitochondrial DNA. 5 For detailed insights in the function and dysfunction of complex I and the affiliated physiological effects, specific inhibitors are irreplaceable agents and valuable biochemical tools. This has led to the identification of a number of inhibitors and their use in binding studies, 6 which already have extensively contributed to the ongoing investigation of the properties of the enzyme and its as yet unsolved dynamic mode of action. 7 Moreover, several modern pesticides, e.g. fenpyroximate, inhibiting complex I have been successfully brought to market. 8 Presently, inhibitors of complex I are worldwide intensely investigated as extrogenous mediators of a wide sprectrum of neurodegenerative disorders, including
Parkinson's disease or progressive supranuclear palsy. 9 Thus, the plant-derived annonacin (1), a member of the acetogenin family, was recently identified as the molecular cause of neurodegenerations (atypical parkinsonism). 10 Synthetic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 2) and the plant-derived rotenone (3) are now regularly used in cell cultures and model studies of Parkinson's disease.
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The enormous structural diversity of known inhibitors of complex I, which also includes microbial myxalamids (e.g., 4) 12 and piericidins (e.g., 5) 13 as well as the fungal verticipyrone (6), 14 has led to attempts to classify these compounds into three fundamental types based on their presumed different modes of inhibition in the ubiquinone redox cycle and thus, different binding sites. 6 However, current hypotheses of the inhibitor binding domain suggest a common large binding pocket, which is constructed by multiple subunits and has several, partially overlapping binding positions for the structurally diverse inhibitor molecules. Yet, the understanding of the competitive behaviour of established complex I inhibitors is hampered by the possibility, that the chemical diverse molecules might either compete for identical binding sites or induce structural dynamic changes in the enzyme which then influence the binding of a second inhibitor. 15, 16 Recently, we reported about the isolation and total synthesis of iromycins A-D, a unique family of α-pyridone metabolites from Streptomyces sp. 17, 18 The striking structural similarities and clear differences with inhibitors 5 and 6 gave rise to evaluate their inhibitory potential and the site of action within the mitochondrial electron transport chain. Herein, we report on the isolation of the new oxidated metabolites E and F, as well as the synthesis of a variety of derivatives that enabled a comprehensive study on the structure-activity relationships (SAR) of the iromycin family.
Organic and biomolecular chemistry
Microbial metabolites and semisynthetic derivatives. The iromycins A-D (7-10) were recently isolated from Streptomyces bottropensis sp. Gö Dra 17 in yields of 18 mg/L (7), 12 mg/L (8), 0.5 mg/L (9) and 0.25 mg/L (10). 17 With their fully substituted heterocyclic moiety and the long unsaturated side chain, they show distinct similarities with both, the ubiquinones as well as verticipyrone (6), that was lately isolated from the fungus Verticillium sp. FKI-1083
as an inhibitor of the NADH fumarate reductase and the complex I. 14 Also structurally related is the piericidin family with about two dozens of compounds. They are produced by different
Streptomyces strains and belong to the most potent inhibitors of complex I of the mitochondrial electron transport chain.
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The iromycins 7-10 already revealed a highly interesting biological activity as selective inhibitors of the nitric oxide synthase (NOS) together with an apparent SAR, since iromycin A (7) with its terminal isopropyl group is a stronger inhibitor than the hydroxylated derivative B (8) or C (9) that possesses just a terminal ethyl group. Moreover, it was shown that iromycin B (8) is the product of an P450-dependent oxidative degradation of iromycin A (7) and thus, iromycin D (10) presumably stems from a similar oxidation of iromycin C (9). 17 These findings prompted a more detailed search for other oxidated metabolites. Cultivations of the producer strain Streptomyces sp. Dra 17 in 10 L and 50 L fermenters under the previously reported conditions led to the isolation of two further members of the iromycin family, which were stained violet with anisaldehyde reagent. 17 Iromycin E (11) was obtained from the culture filtrate by extraction with EtOAc, silica gel chromatography, gel chromatography (Sephadex LH20), and reverse phase HPLC in an amount of 0.25 mg/L.
Iromycin F (12) was separated from the fraction mainly containing iromycin A (7) by reverse phase HPLC (0.38 mg/L). Structure elucidation was performed using mass spectrometry and NMR methods, and data were compared to that of iromycin A. The non-natural derivatives iromycin AH (13), AM (14) , BM (15), AA (16) , and BA (17) were prepared from the microbial metabolites iromycin A (7) and B (8) which can be isolated from Streptomyces sp. Dra 17 in reasonable amounts. 17 General protocols for the hydrogenation with H 2 over Pd/C, the methylation with diazomethane, and the acetylation with acetic anhydride were applied. 17 Thus, another five iromycin analogues with chemical changes in the side chain as well as in the heterocyclic core were obtained as pure compounds and used for structural characterization and biological profiling.
Total synthesis. The structural novelty and promising biological activity of the iromycins made their total synthesis an attractive aim. Therefore, a highly convergent access to these compounds was developed, that consists of a coupling of the heterocyclic moiety as a pyrone derivative with the side chains as alkenyl alanates on a late stage of the synthesis and already led to the formation of iromycin A (7) in 18% overall yield and non-natural iromycin M (18) in 14% overall yield. 18 As the NOS inhibition potential of the iromycins increases with the steric bulk of the end cap of the side chain -which could be the consequence of a higher lipophilicity -the synthesis of the respective tert-butyl derivative, iromycin S (20), was envisaged and thus of a derivative, which should also resist the degradation by side chain hydroxylation. 
Effects on the mitochondrial electron transport and biological profile
The iromycins and their pyrone analogues 7-22 were investigated for their potential to act as electron transport inhibitors by testing their inhibitory efficacy on NADH oxidation in beef heart submitochondrial particles (SMP) ( Table 1 and Figure 1 ). Piericidin A 1 (5) was included as a control. As anticipated from the structural analogies, some iromycins indeed significantly blocked the mitochondrial electron transport, in particular the natural iromycins 7, 9, the semisynthetic 13, 14 and synthetic agents 18, 20. As shown in Figure 1 iromycin A (7) inhibited NADH oxidation half-maximally (IC 50 ) at a concentration of 140 ng/mL (0.461 μM). The IC 50 value for piericidin A 1 (5) in the same test system was 2.1 ng/ml (0.0050 µM), which is comparable with the values given in the literature. 13 Metabolite 7 with its isopropyl group as end cap is 7-fold more potent than 9
(IC 50 = 1020 ng/mL, 3.5 μM) with its less branched side chain. Compared to those, the 7"-hydroxylated metabolites 8 and 10, and the ring oxidated analogues 11 and 12 display no significant inhibitory activity. Hydrogenation and methylation of iromycin A (analogues 13 and 14) reduces the potency by a factor of 5-6. In contrast, the other semisynthetic derivatives 15-17 as well as the synthetic pyrone intermediates 19, 21 and 22 are not active. Remarkably, iromycin M (18) resembling a 5",6"-dihydroanalogue of iromycin C (9) is 3.5-fold more potent than the latter. Yet, the most potent of all these congeners is iromycin S (20) , that carries a more bulky t-butyl group in the side chain and is about 2.5-fold more active in the complex I inhibition assay than the natural metabolite 7. No activity was observed for iromycins A (7) and B (8) in a test panel for herbicide, insecticide und fungicide activity. To evaluate the cytotoxic potential, compounds 7 and 8
were tested on cancer cell lines HM02 (gastric adenocarcinoma), HepG2 (hepatocellular carcinoma) and MCF7 (breast adenocarcinoma) corresponding NCI-directives, but showed no activity (IC 50 > 10 µg/mL (> 30μM)). Moreover, 7 is known to be non-toxic upon intraperitoneal injection in mice (100 mg/kg). 22 In addition, we checked the cytotoxicity of 5, 7, 8, 18, and 20 in parallel, using L929 mouse fibroblasts, 23 All results demonstrate that even the most potent compound of the iromycin family shows only marginal cytotoxicity in comparison to piericidin A 1 (5).
Discussion of structure-activity relationships
Isolated as a group of metabolites from Streptomyces sp. the piericidins (e.g., 5) feature a 'cyclic head', i.e. the fully substituted 4-hydroxypyridine core, together with a 'hydrophobic tail', the branched, unsaturated side chain. They have been widely recognized as a highly active complex I inhibitors. They exhibit promising biological activity in a broad range as insecticides, antimicrobial or antifungal agents and also as inhibitors of immune response proteins. Additionally, the highly selective antitumor activity and great potency of certain piericidins prompted a detailed investigation of SAR. 13, 19, 24, 25, 26 However, the different mechanisms of action have yet not been established, and the high chemical instability and significant cytotoxicity of the piericidins impairs their broad use in biochemical studies.
The iromycins possess similar structural features as the piericidins (e.g, 5) and verticipyrone (6), in particular a heterocyclic core structure and a side chain with a non-conjugated double bond in β,γ-position to the ring. However, the distinct differences between the compounds investigated in this study allow for the discussion of structure-activity relationships with the 
Conclusion
New iromycins have been isolated and synthesized. To determine structure-activity relationships, their efficacy on NADH oxidation in beef heart SMP was tested in comparison to iromycin A (7) and piericidin A 1 (5) . The inhibitory potential of the iromycins is clearly modulated by the structural features discussed here and shows analogies with the piericidins.
However, some pronounced differences between both metabolite families were stated.
Especially the different cytotoxic potential is striking and provides another hint, that the high toxicity of the piericidins is most-likely not caused only by their complex I-inhibition. 13 Moreover, a vasodilating activity was noted for some piericidins, 28 while the iromycins are presumably vasoconstrictors due to their inhibition of the NOS. 17 Clearly, more detailed investigations are necessary to both, broadly evaluate and then understand the biological profile of these Streptomyces metabolites. This includes competitive binding studies of the iromycins and known inhibitors. With the established total synthesis at hand, we are now working towards the preparation of hybrids of the iromycins and piericidins, and additional analogues should be obtained from precursor-directed biosynthesis.
Altogether, the new iromycin family sets the stage for the identification of potent but noncytotoxic complex I-inhibitors which would be ideal biochemical tools not only for the investigation of the complex I enzyme, but also for pharmacological relevant studies on neurodegenerative diseases.
Experimental Section
General Experimental Methods. Fermentations, extractions and column chromatography were performed as described elsewhere. 17 For special equipment and solvents, see (14) and AA (16), 17 iromycin M (18) and 4-benzoyloxy-6-bromomethyl-3-methyl-5-propylpyran-2-one (28), 18 and (E)-1-bromo-4,4-dimethylpent-2-ene (29) 20 were prepared as described in the literature.
Mitochondrial preparations. Submitochondrial particles of bovine heart (SMP) were obtained by ultrasonic treatment of the mitochondria, which were isolated by differential centrifugation, following the protocol of Smith by using a blender to homogenize the heart mince. 30 The initial homogenisation buffer consisted of 250 mM sucrose, 10 mM KH 2 PO 4 , 10 mM Tris, 2 mM EGTA, 2 mM MgCl 2 , pH 7.4. Further isolation procedures were carried out in the same medium without EGTA.
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Measurements of NADH-oxidation and difference spectra. In both assays, SMP were suspended in 75 mM air saturated sodium potassium phosphate buffer pH 7. 
